November 2016 Issue Table Of Contents

From The Editor

• Despite Public Sentiment, Biopharma Has Many Bright Spots

Feature Articles

• Sanofi Genzyme: Expanding Beyond Rare Disease Into Specialty Care
• How J&J Approached Clinical Trial Data Sharing
• 5 Questions With Allergan’s Chief R&D Officer

Capitol Perspectives

• Leaked Emails, Physician Reg Signal Risks For Rx Industry

Companies To Watch

• Why Now Is A Pivotal Time For Rare-Disease Pharma Catabasis

CEO Corner

• Can Financial Markets Solve The Ever-Increasing Costs of Healthcare?

Inside The Industry

• Women In Bio: Looking Through The Glass Ceiling
• Why An Investment Banker Returned To Drug Development
• What’s Luring Pharma Back Into Antibiotic R&D?
• Clinical Trials In China: A Model For Advancing Cancer Therapies
• The MENA Pharma Market: An Untapped Opportunity

Leadership Lessons

• Management Is Dead. Stop Managing And Start Coaching!

Industry Leader

• Active Targeting: A New Wave In Drug Delivery
• The Space Squeeze: One Challenge In Building A Biopharm Lab

Ask The Board

• What Are The Biggest Challenges To Biopharma Companies In Trying To Be Patient-Centric, And What Advice Would You Give For How To Achieve Their Patient-Centric Goals?
• What Are Some Challenges Surrounding The Operationalization Of The Data-Sharing Mandate Posed By The International Committee Of Medical Journal Editors (ICMJE)?
• Knowing What You Know Now, What Would You Do Differently When Growing Your Company?